

Contents

| | |
|---|-----|
| Contributors | ix |
| Part I Introduction | |
| Historical Development of Monoclonal Antibody Therapeutics | 3 |
| A. Nissim and Y. Chernajovsky | |
| Preclinical Safety Evaluation of Monoclonal Antibodies | 19 |
| C.M. Lynch and I.S. Grewal | |
| Part II Molecular Developments in Antibody Production | |
| Engineering Antibodies for Stability and Efficient Folding | 47 |
| A. Honegger | |
| Human Monoclonal Antibodies from Transgenic Mice | 69 |
| N. Lonberg | |
| Part III Antibodies to Cytokines | |
| Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future ... | 101 |
| D.J. Shealy and S. Visvanathan | |
| Therapeutic Anti-VEGF Antibodies | 131 |
| S. Lien and H.B. Lowman | |
| Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab | 151 |
| N. Nishimoto and T. Kishimoto | |

Part IV Antibodies to Cell Markers

Anti-CD20 Monoclonal Antibody in Rheumatoid Arthritis and Systemic Lupus Erythematosus 163
F. Goldblatt and D.A. Isenberg

Herceptin 183
H.M. Shepard, P. Jin, D.J. Slamon, Z. Pirot, and D.C. Maneval

The Use of CD3-Specific Antibodies in Autoimmune Diabetes: A Step Toward the Induction of Immune Tolerance in the Clinic 221
L. Chatenoud

Monoclonal Antibody Therapy for Prostate Cancer 237
A. Jakobovits

Anti-IgE and Other Antibody Targets in Asthma 257
J. Singh and M. Kraft

Part V Development of Antibody-Based Cellular and Molecular Therapies

Cytokine, Chemokine, and Co-Stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors 291
L.A. Khawli, P. Hu, and A.L. Epstein

The T-Body Approach: Redirecting T Cells with Antibody Specificity 329
Z. Eshhar

Intracellular Antibodies (Intrabodies) and Their Therapeutic Potential . . 343
A.S.-Y. Lo, Q. Zhu, and W.A. Marasco

Index 375